- Lenzilumab plus standard of care (SOC), resulted in an estimated cost savings of $13,190 per patient (net savings of $3,190, after an assumed price of $10,000 for lenzilumab) in those receiving remdesivir with baseline C-Reactive Protein (CRP) levels <150 mg/L, and aged <85 years
- For COVID-19 patients requiring ICU admission and invasive mechanical ventilation, the average healthcare cost is $78,245 per patient
- Despite increasing vaccinations, the number of COVID-19 cases, hospitalizations and deaths continues to increase, demonstrating the urgent need for both clinically effective and cost-effective variant-agnostic treatments for hospitalized patients
BURLINGAME, Calif., January 18, 2022–(BUSINESS WIRE)–Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced a peer-reviewed publication in the Journal of Medical Economics (https://www.tandfonline.com/doi/full/10.1080/13696998.2022.2030148) citing the clinical and associated health economic benefits of lenzilumab. The publication demonstrated, in all cases, lenzilumab plus SOC improved all specified clinical outcomes compared with SOC alone. Lenzilumab plus SOC, resulted in an estimated cost savings of $13,190 per patient (net savings of $3,190, after an assumed price of $10,000 for lenzilumab) in those receiving remdesivir with baseline C-Reactive Protein (CRP) levels <150 mg/L, and aged <85 years, the primary analysis population in the fully enrolled ACTIV-5/BET-B study. In other subpopulations, per-patient savings were also observed, including those aged <85 years with baseline CRP <150mg/L with or without remdesivir (cost savings = $11,858, net cost savings = $1,858) and within the subpopulation of Black/African American patients with baseline CRP <150mg/L (cost savings = $23,154, net cost savings = $13,154).
“This publication demonstrates the opportunity to…